- Documentoinforme (1)caricato daalvaro.bosch.ibanez
- Documentoinformecaricato daalvaro.bosch.ibanez
- Documentojamaneurology_mendell_2021_oi_210023_1624467431.00495caricato daalvaro.bosch.ibanez
- Documentoinforme (2)caricato daalvaro.bosch.ibanez
- DocumentoAtrofia_muscular_espinalcaricato daalvaro.bosch.ibanez
- DocumentoGil Lizarraga, Uxuecaricato daalvaro.bosch.ibanez
- DocumentoSpinal Muscular Atrophycaricato daalvaro.bosch.ibanez
- DocumentoSpinal muscular atrophy From approved therapies to future therapeutic targets for personalized medicinecaricato daalvaro.bosch.ibanez
- DocumentoSafety and efficacy of nusinersen in spinal muscular atrophy The EMBRACE studycaricato daalvaro.bosch.ibanez
- DocumentoNew and Developing Therapies in Spinal Muscularcaricato daalvaro.bosch.ibanez
- DocumentoExpert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophycaricato daalvaro.bosch.ibanez
- DocumentoAdvances and limitations for the treatment of spinal muscular atrophycaricato daalvaro.bosch.ibanez
- DocumentoFive-Year Extension Results of the Phase 1 START Trialcaricato daalvaro.bosch.ibanez